Protecting the Fetus Against HIV Infection: A Systematic Review of Placental Transfer of Antiretrovirals

Clinical Pharmacokinetics

Volumn 53, Issue 11, 2014, Pages 989-1004

  McCormack, Shelley A ^a   Best, Brookie M ^a,b  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG BINDING PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; 2 PYRROLIDONE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR;

DRUG BLOOD LEVEL; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MATERNAL PLASMA; PLACENTA PERFUSION; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UMBILICAL CORD BLOOD; ANIMAL; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; HIV INFECTIONS; METABOLISM; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; TRANSMISSION; UNITED STATES; VERTICAL TRANSMISSION; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; FEMALE; FETUS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRROLIDINONES; RALTEGRAVIR POTASSIUM; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; UNITED STATES;

EID: 84920997085     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0185-7     Document Type: Review

References (111)

1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. U.S. Department of Health and Human Services and NIH. 2014. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed 10 Apr 2014.
2. Tubiana R, Le Chenadec J, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case–control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis. 2010;50(4):585–96. doi:10.1086/650005.
3. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(3):458–65. doi:10.1086/427287.
4. Launay O, Tod M, Tschope I, Si-Mohamed A, Belarbi L, Charpentier C, et al. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther. 2011;16(6):843–52. doi:10.3851/IMP1856.
5. Carter AM. Animal models of human placentation—a review. Placenta. 2007;28(Suppl A):S41–7. doi:10.1016/j.placenta.2006.11.002.
6. Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006;20(4):553–60. doi:10.1097/01.aids.0000210609.52836.d1.
7. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48(11):4332–6. doi:10.1128/AAC.48.11.4332-4336.2004.
8. Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol. 2001;41(7):732–41.
9. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol. 2001;184(2):153–8. doi:10.1067/mob.2001.108344.
10. Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother. 2009;53(6):2367–74. doi:10.1128/AAC.01523-08.
11. Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother. 2012;56(2):776–82. doi:10.1128/AAC.00370-11.
12. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, Yasin S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004;190(12):2167–74. doi:10.1086/425903.
13. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012;13(4):226–35. doi:10.1111/j.1468-1293.2011.00965.x.
14. Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27(5):739–48. doi:10.1097/QAD.0b013e32835c208b.
15. Calcagno A, Trentini L, Marinaro L, Montrucchio C, D’Avolio A, Ghisetti V, et al. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. J Antimicrob Chemother. 2013;68(8):1938–9. doi:10.1093/jac/dkt095.
16. Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014;65(1):33–41. doi:10.1097/QAI.0b013e3182a921eb.
17. Beigi R, Noguchi L, Parsons T, Macio I, Kunjara Na Ayudhya RP, Chen J, et al. Pharmacokinetics and placental transfer of single-dose tenofovir 1 % vaginal gel in term pregnancy. J Infect Dis. 2011;204(10):1527–31. doi:10.1093/infdis/jir562.
18. Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis. 1991;163(2):226–32.
19. Sperling RS, Roboz J, Dische R, Silides D, Holzman I, Jew E. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol. 1992;9(4):247–9. doi:10.1055/s-2007-994781.
20. O’Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol. 1993;168(5):1510–6.
21. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178(5):1327–33.
22. Rodman JH, Flynn PM, Robbins B, Jimenez E, Bardeguez AD, Rodriguez JF, et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants. J Infect Dis. 1999;180(6):1844–50. doi:10.1086/315152.
23. Bhadrakom C, Simonds RJ, Mei JV, Asavapiriyanont S, Sangtaweesin V, Vanprapar N, et al. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS. 2000;14(5):509–16.
24. Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandia J, Hitti J, et al. Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. HIV Med. 2007;8(7):451–6. doi:10.1111/j.1468-1293.2007.00495.x.
25. Siu SS, Yeung JH, Pang MW, Chiu PY, Lau TK. Placental transfer of zidovudine in first trimester of pregnancy. Obstet Gynecol. 2005;106(4):824–7. doi:10.1097/01.AOG.0000178160.38042.04.
26. Gillet JY, Bongain A, Abrar D, Garraffo R, Lapalus P. Preliminary study on the transport of AZT (retrovir-zidovudine) through the placenta. J Gynecol Obstet Biol Reprod (Paris). 1990;19(2):177–80.
27. Pons JC, Taburet AM, Singlas E, Delfraissy JF, Papiernik E. Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Eur J Obstet Gynecol Reprod Biol. 1991;40(3):229–31.
28. Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012;59(3):245–52. doi:10.1097/QAI.0b013e31823ff052.
29. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013;63(5):578–84. doi:10.1097/QAI.0b013e31829c48ad.
30. Izurieta P, Kakuda TN, Feys C, Witek J. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 2011;12(4):257–8. doi:10.1111/j.1468-1293.2010.00874.x.
31. Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS. 2009;23(3):434–5. doi:10.1097/QAD.0b013e32832027d6.
32. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al. Transplacental passage of protease inhibitors at delivery. AIDS. 2002;16(6):889–93.
33. Gingelmaier A, Kurowski M, Kastner R, Eberle J, Mylonas I, Belohradsky BH, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20(13):1737–43. doi:10.1097/01.aids.0000242820.67001.2c.
34. Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008;9(4):214–20. doi:10.1111/j.1468-1293.2008.00553.x.
35. Ivanovic J, Nicastri E, Anceschi MM, Ascenzi P, Signore F, Pisani G, et al. Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Curr HIV Res. 2009;7(6):620–5.
36. van Hoog S, Boer K, Nellen J, Scherpbier H, Godfried MH. Transplacental passage of nevirapine, nelfinavir and lopinavir. Neth J Med. 2012;70(2):102–3.
37. Taylor GP, Lyall EGH, Back D, Ward C, Tudor-Williams G. Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet. 2000;355(9221):2134–5.
38. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178(2):368–74.
39. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13(4):479–86.
40. Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003;33(2):153–6.
41. Benaboud S, Ekouevi DK, Urien S, Rey E, Arrive E, Blanche S, et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2011;55(1):331–7. doi:10.1128/AAC.00631-10.
42. Colbers A, Gingelmaier A, van de Ende M, Rijnders B, Burger D. Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases. AIDS. 2014;28(2):288–90. doi:10.1097/QAD.0000000000000100.
43. Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007;21(18):2409–15. doi:10.1097/QAD.0b013e32825a69d1.
44. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56(5):412–9. doi:10.1097/QAI.0b013e31820fd093.
45. Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol. 2011;157(1):18–21. doi:10.1016/j.ejogrb.2011.02.005.
46. Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med. 2011;12(9):570–9. doi:10.1111/j.1468-1293.2011.00927.x.
47. Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, et al. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr. 2013;63(1):59–66. doi:10.1097/QAI.0b013e318289b4d2.
48. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: a case report. AIDS. 2006;20(2):307.
49. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20(15):1931–9. doi:10.1097/01.aids.0000247114.43714.90.
50. Croci L, Trezzi M, Allegri MP, Carli T, Chigiotti S, Riccardi MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol. 2012;68(8):1231–2. doi:10.1007/s00228-012-1250-5.
51. Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother. 2012;56(2):816–24. doi:10.1128/AAC.05186-11.
52. Fayet-Mello A, Buclin T, Guignard N, Cruchon S, Cavassini M, Grawe C, et al. Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women. Antivir Ther. 2013;18(2):171–82. doi:10.3851/IMP2328.
53. Santini-Oliveira M, Estrela Rde C, Veloso VG, Cattani VB, Yanavich C, Velasque L, et al. Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. Antimicrob Agents Chemother. 2014;58(5):2884–93. doi:10.1128/AAC.02599-13.
54. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008;49(5):485–91. doi:10.1097/QAI.0b013e318186edd0.
55. Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54(4):381–8.
56. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002;21(9):835–8. doi:10.1097/01.inf.0000027591.04920.c7.
57. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004;191(2):558–62. doi:10.1016/j.ajog.2004.01.034.
58. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther. 2004;76(6):588–97. doi:10.1016/j.clpt.2004.08.011.
59. Villani P, Floridia M, Pirillo MF, Cusato M, Tamburrini E, Cavaliere AF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62(3):309–15. doi:10.1111/j.1365-2125.2006.02669.x.
60. Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, et al. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. Br J Clin Pharmacol. 2007;64(5):634–44. doi:10.1111/j.1365-2125.2007.02885.x.
61. Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008;9(2):115–25. doi:10.1310/hct0902-115.
62. Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008;9(10):875–82. doi:10.1111/j.1468-1293.2008.00640.x.
63. Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, et al. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol. 2013;76(3):475–83. doi:10.1111/bcp.12078.
64. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2(6):460–5.
65. Vithayasai V, Moyle GJ, Supajatura V, Wattanatchariya N, Kanshana S, Sirichthaporn P, et al. Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr. 2002;30(4):410–2.
66. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48(2):430–6.
67. Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS. 2009;20(3):215–6. doi:10.1258/ijsa.2008.008515.
68. Ivanovic J, Bellagamba R, Nicastri E, Signore F, Vallone C, Tempestilli M, et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS. 2010;24(7):1083–4. doi:10.1097/QAD.0b013e32833653b2.
69. Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther. 2010;15(1):127–9. doi:10.3851/IMP1473.
70. Zorrilla CD, Wright R, Osiyemi OO, Yasin S, Baugh B, Brown K, et al. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily. HIV Med. 2014;15(1):50–6. doi:10.1111/hiv.12047.
71. Cespedes MS, Castor D, Ford SL, Lee D, Lou Y, Pakes GE, et al. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr. 2013;62(5):550–4. doi:10.1097/QAI.0b013e318285d918.
72. Weizsaecker K, Kurowski M, Hoffmeister B, Schurmann D, Feiterna-Sperling C. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int J STD AIDS. 2011;22(5):294–5. doi:10.1258/ijsa.2009.009166.
73. Brennan-Benson P, Pakianathan M, Rice P, Bonora S, Chakraborty R, Sharland M, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS. 2006;20(2):297–9. doi:10.1097/01.aids.0000200535.02232.1b.
74. Jeantils V, Alloui C, Rodrigues A, Bentata M, Peytavin G, Carbillon L. Use of enfurvitide in pregnancy in HIV positive women in seven cases. Gynecol Obstet Fertil. 2009;37(5):396–400. doi:10.1016/j.gyobfe.2009.03.013.
75. McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS. 2010;24(15):2416–8. doi:10.1097/QAD.0b013e32833d8a50.
76. Hegazi A, Mc Keown D, Doerholt K, Donaghy S, Sadiq ST, Hay P. Raltegravir in the prevention of mother-to-child transmission of HIV-1: effective transplacental transfer and delayed plasma clearance observed in preterm neonates. AIDS. 2012;26(18):2421–3. doi:10.1097/QAD.0b013e32835a9aeb.
77. Hirt D, Urien S, Rey E, Arrive E, Ekouevi DK, Coffie P, et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2009;53(3):1067–73. doi:10.1128/AAC.00860-08.
78. Hirt D, Pruvost A, Ekouevi DK, Urien S, Arrive E, Kone M, et al. Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Antimicrob Agents Chemother. 2011;55(6):2953–60. doi:10.1128/AAC.01376-10.
79. Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, Blanche S, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009;85(2):182–9. doi:10.1038/clpt.2008.201.
80. Hirt D, Ekouevi DK, Pruvost A, Urien S, Arrive E, Blanche S, et al. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother. 2011;55(6):2961–7. doi:10.1128/AAC.01377-10.
81. Frank M, Harms G, Kunz A, Kloft C. Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. J Clin Pharmacol. 2013;53(3):294–304. doi:10.1177/0091270012448397.
82. Bawdon RE. The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect Dis Obstet Gynecol. 1998;6(6):244–6. doi:10.1155/S1064744998000507.
83. Bawdon RE, Sobhi S, Dax J. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol. 1992;167(6):1570–4.
84. Dancis J, Lee JD, Mendoza S, Liebes L. Transfer and metabolism of dideoxyinosine by the perfused human placenta. J Acquir Immune Defic Syndr. 1993;6(1):2–6.
85. Henderson GI, Perez AB, Yang Y, Hamby RL, Schenken RS, Schenker S. Transfer of dideoxyinosine across the human isolated placenta. Br J Clin Pharmacol. 1994;38(3):237–42.
86. Bloom SL, Dias KM, Bawdon RE, Gilstrap LC 3rd. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol. 1997;176(2):291–3.
87. Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest. 1994;38(1):1–4.
88. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol. 1998;179(3 Pt 1):758–61.
89. Boal JH, Plessinger MA, van den Reydt C, Miller RK. Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Toxicol Appl Pharmacol. 1997;143(1):13–21. doi:10.1006/taap.1996.8046.
90. Olivero OA, Parikka R, Poirier MC, Vahakangas K. 3′-azido-3′-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT. Mutat Res. 1999;428(1–2):41–7.
91. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001;185(1):178–81. doi:10.1067/mob.2001.113319.
92. Rahi M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, et al. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. Hum Exp Toxicol. 2008;27(1):65–71. doi:10.1177/0960327108088971.
93. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, et al. Functional role of P-glycoprotein in the human blood–placental barrier. Clin Pharmacol Ther. 2005;78(2):123–31. doi:10.1016/j.clpt.2005.04.014.
94. Rahi MM, Heikkinen TM, Hakala KE, Laine KP. The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placenta. Eur J Pharm Sci. 2009;37(5):588–92. doi:10.1016/j.ejps.2009.05.005.
95. Sudhakaran S, Ghabrial H, Nation RL, Kong DC, Gude NM, Angus PW, et al. Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother. 2005;49(3):1023–8. doi:10.1128/AAC.49.3.1023-1028.2005.
96. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol. 2008;65(5):667–73. doi:10.1111/j.1365-2125.2007.03067.x.
97. Gavard L, Gil S, Peytavin G, Ceccaldi PF, Ferreira C, Farinotti R, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol. 2006;195(1):296–301. doi:10.1016/j.ajog.2006.01.017.
98. Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, et al. Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):157–60. doi:10.1016/j.ejogrb.2009.08.007.
99. Vinot C, Gavard L, Treluyer JM, Manceau S, Courbon E, Scherrmann JM, et al. Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob Agents Chemother. 2013;57(3):1415–20. doi:10.1128/AAC.01821-12.
100. Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol. 2008;198(4):433 e1–2. doi:10.1016/j.ajog.2007.10.802.
101. Nishimura T, Seki Y, Sato K, Chishu T, Kose N, Terasaki T, et al. Enhancement of zidovudine uptake by dehydroepiandrosterone sulfate in rat syncytiotrophoblast cell line TR-TBT 18d-1. Drug Metab Dispos. 2008;36(10):2080–5. doi:10.1124/dmd.108.021345.
102. Plessinger MA, Boal JH, Miller RK. Human placenta does not reduce AZT (zidovudine) to 3′-amino-3′-deoxythymidine. Proc Soc Exp Biol Med. 1997;215(3):243–7.
103. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Baker R, Stek AM, et al. Incorporation of zidovudine into cord blood DNA of infants and peripheral blood DNA of their HIV-1-positive mothers. Ann NY Acad Sci. 2000;918:262–8.
104. Andre-Schmutz I, Dal-Cortivo L, Six E, Kaltenbach S, Cocchiarella F, Le Chenadec J, et al. Genotoxic signature in cord blood cells of newborns exposed in utero to a zidovudine-based antiretroviral combination. J Infect Dis. 2013;208(2):235–43. doi:10.1093/infdis/jit149.
105. Camus M, Delomenie C, Didier N, Faye A, Gil S, Dauge MC, et al. Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. Placenta. 2006;27(6–7):699–706. doi:10.1016/j.placenta.2005.08.001.
106. Neumanova Z, Cerveny L, Ceckova M, Staud F. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014;28(1):9–17. doi:10.1097/QAD.0000000000000112.
107. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. Br J Clin Pharmacol. 2007;63(3):315–21. doi:10.1111/j.1365-2125.2006.02766.x.
108. Gulati A, Boudinot FD, Gerk PM. Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin. Drug Metab Dispos. 2009;37(8):1572–5. doi:10.1124/dmd.109.026708.
109. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48(2):437–43.
110. Drusano GL, Bilello JA, Preston SL, O’Mara E, Kaul S, Schnittman S, et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis. 2001;183(7):1126–9. doi:10.1086/319281.
111. Acosta EP, Limoli KL, Trinh L, Parkin NT, King JR, Weidler JM, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother. 2012;56(11):5938–45. doi:10.1128/AAC.00691-12.